When does curatively treated colorectal cancer recur? An Australian perspective

Reece, Mifanwy; Chapuis, Pierre; Keshava, Anil; Stewart, Peter; Suen, Michael; Rickard, Matthew J. F. X.

doi:10.1111/ans.14870

Cited by 10 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Between 70% and 90% of the recurrences are detected within the first 3 years after surgery. [2][3][4][5][6][7][8][9] In Denmark and many other countries, CRC recurrence is not recorded routinely in clinical databases or nationwide healthcare registries. Therefore, Lash et al developed and validated an algorithm combining data from different Danish registries to identify CRC recurrences for the period 2001-2011.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identifying Recurrences Among Non-Metastatic Colorectal Cancer Patients Using National Health Data Registries: Validation and Optimization of a Registry-Based Algorithm in a Modern Danish Cohort

Nors¹,

Mattesen²,

Cronin-Fenton³

et al. 2023

CLEP

View full text Add to dashboard Cite

Purpose: Colorectal cancer (CRC) recurrence is not routinely recorded in Danish health data registries. Here, we aimed to revalidate a registry-based algorithm to identify recurrences in a contemporary cohort and to investigate the accuracy of estimating the time to recurrence (TTR). Patients and Methods: We ascertained data on 1129 patients operated for UICC TNM stage I-III CRC during 2012-2017 registered in the CRC biobank at the

show abstract

Section: Introductionmentioning

confidence: 99%

“…Three years of complete follow-up would be preferable as 90% of all recurrences occur within this timeframe. [2][3][4][5][6][7][8][9]…”

mentioning

confidence: 99%

Identifying Recurrences Among Non-Metastatic Colorectal Cancer Patients Using National Health Data Registries: Validation and Optimization of a Registry-Based Algorithm in a Modern Danish Cohort

Nors¹,

Mattesen²,

Cronin-Fenton³

et al. 2023

CLEP

View full text Add to dashboard Cite

show abstract

“…Specifically, our cohort was divided into those ≤2 years from their index surgery and those who were >2 years. A cutoff of 2 years was chosen as studies have demonstrated that over 50% of CRC patients recur within this time frame [23]. Optum software was used to transform SF‐36v2 question answers into norm‐based PCS and MCS scores.…”

Section: Methodsmentioning

confidence: 99%

The health‐related quality of life of early‐onset colorectal cancer patients: an Australian cross‐sectional study

Garrett,

Koh,

Solomon

et al. 2024

Colorectal Disease

View full text Add to dashboard Cite

AimEarly‐onset colorectal cancer (EOCRC) patients are more likely to have advanced disease and undergo more aggressive treatment modalities. However, current literature investigating the health‐related quality of life (HRQoL) of EOCRC patients is scarce. This study aimed to determine the HRQoL of an Australian cohort of EOCRC patients including a subset who underwent pelvic exenteration (PE) or cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).MethodA cross‐sectional study of EOCRC patients treated at the Royal Prince Alfred Hospital, Sydney Australia was performed. Patients were divided into groups based on the time interval from their index operation: ≤2 years and >2 years. HRQoL was evaluated using the SF‐36v2 questionnaire.ResultsA total of 50 patients were included. For patients ≤2 years from surgery, the median physical component summary (PCS) and mental health component summary (MCS) scores were 53.3 (36.4–58.9) and 47.3 (37.5–55.7). In the >2 years group, the median PCS and MCS scores were 50.6 (43.3–57.7) and 50.2 (39.04–56.2), respectively. Stage I (vs. stage II) disease and emergency (vs. elective) surgery conferred poorer PCS scores in patients ≤2 years from surgery. No other variables impacted PCS or MCS scores in EOCRC patients in either group.ConclusionsHRQoL of EOCRC patients was equivocal to the Australian population. Having an earlier stage of diagnosis and emergency index operation was associated with poorer levels of physical functioning in patients ≤2 years from surgery. However, because of the limitations of this study, these findings require validation in future large‐scale prospective research.

show abstract

“…Approximately 20%–25% of patients present with synchronous metastases, and a significant proportion of stages I–III will develop metachronous metastases (MM) 2–7 . These are mainly detected during the first 3 years after primary surgery 8 …”

Section: Introductionmentioning

confidence: 99%

A systematic review of population‐based studies on metachronous metastases of colorectal cancer

Nyström,

Olsson

2024

World j. surg.

View full text Add to dashboard Cite

BackgroundThe occurrence of metachronous metastases (MM) of colorectal (CRC), colon (CC), and rectal (RC) cancer of population‐based studies has not been compiled in a systematic review previously.MethodsMEDLINE, Embase, and Cochrane Library were searched for primary studies of any design from inception until January 2021 and updated in August 2023 (CRD42021261648). The PRISMA guidelines were adopted, and the Newcastle‐Ottawa Quality Assessment Scale used for risk of bias assessment. Outcomes on overall and organ‐specific MM were extracted. A narrative analysis followed.ResultsOut of 2143 unique hits, 162 publications were read in full‐text and 37 population‐based cohort studies published in 1981–2022 were included. Ten studies adopted time‐dependent analyses; eight were registry‐based and seven had a low risk of bias. Three studies reported 5‐year recurrence rate of MM overall of stages I–III; for CRC, it was 20.5%, for CC, it was 18% and 25.6%, and for RC, it was 23%. Four studies reported 5‐year recurrence rate of organ‐specific MM of stages I–III—for CRC, it was 2.2% and 5.5% for peritoneal metastases and 5.8% for lung metastases and for CC 4.5% for peritoneal metastases. Twenty‐seven studies reported proportions of patients diagnosed with MM, but data on the length of follow‐up was incomplete and varied widely. Proportions of patients with CRC stages I–III that developed MM overall was 14.4%–26.1% in 10 studies. In relation to the enrollment period, a downward trend may be discernible.ConclusionStudies adopting a more appropriate analysis were highly heterogeneous, whereas uncertain data of partly inadequate studies may indicate that MM are overall declining.

show abstract

When does curatively treated colorectal cancer recur? An Australian perspective

Cited by 10 publications

References 33 publications

Identifying Recurrences Among Non-Metastatic Colorectal Cancer Patients Using National Health Data Registries: Validation and Optimization of a Registry-Based Algorithm in a Modern Danish Cohort

Identifying Recurrences Among Non-Metastatic Colorectal Cancer Patients Using National Health Data Registries: Validation and Optimization of a Registry-Based Algorithm in a Modern Danish Cohort

The health‐related quality of life of early‐onset colorectal cancer patients: an Australian cross‐sectional study

A systematic review of population‐based studies on metachronous metastases of colorectal cancer

Contact Info

Product

Resources

About